Q2 2025 EPS Estimates for Patterson Companies, Inc. (NASDAQ:PDCO) Decreased by Analyst

Patterson Companies, Inc. (NASDAQ:PDCO) – Analysts at Zacks Research dropped their Q2 2025 earnings per share (EPS) estimates for Patterson Companies in a research note issued to investors on Tuesday, September 10th. Zacks Research analyst I. Bandyopadhyay now expects that the company will post earnings of $0.50 per share for the quarter, down from their previous forecast of $0.53. The consensus estimate for Patterson Companies’ current full-year earnings is $2.33 per share. Zacks Research also issued estimates for Patterson Companies’ Q3 2025 earnings at $0.65 EPS, Q1 2026 earnings at $0.28 EPS, Q2 2026 earnings at $0.48 EPS and Q1 2027 earnings at $0.32 EPS.

Patterson Companies (NASDAQ:PDCO) last announced its quarterly earnings results on Wednesday, August 28th. The company reported $0.24 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.08). Patterson Companies had a net margin of 2.58% and a return on equity of 19.87%. The business had revenue of $1.54 billion for the quarter, compared to the consensus estimate of $1.59 billion. During the same quarter last year, the firm posted $0.40 EPS. The business’s revenue for the quarter was down 2.3% compared to the same quarter last year.

A number of other analysts have also commented on the company. UBS Group decreased their price objective on Patterson Companies from $27.00 to $24.00 and set a “neutral” rating for the company in a report on Thursday, September 5th. StockNews.com lowered Patterson Companies from a “buy” rating to a “hold” rating in a research report on Saturday, June 1st. Bank of America dropped their price objective on Patterson Companies from $31.00 to $29.00 and set a “buy” rating on the stock in a research note on Thursday, August 29th. JPMorgan Chase & Co. reduced their target price on shares of Patterson Companies from $29.00 to $26.00 and set a “neutral” rating for the company in a research note on Thursday, August 29th. Finally, Morgan Stanley dropped their price target on shares of Patterson Companies from $30.00 to $28.00 and set an “equal weight” rating on the stock in a research report on Thursday, June 20th. Nine equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $28.40.

Patterson Companies Trading Up 1.6 %

NASDAQ:PDCO opened at $21.09 on Thursday. The company has a debt-to-equity ratio of 0.34, a current ratio of 1.30 and a quick ratio of 0.67. Patterson Companies has a one year low of $19.96 and a one year high of $32.58. The company has a market cap of $1.85 billion, a PE ratio of 10.55, a PEG ratio of 1.50 and a beta of 1.02. The firm has a 50-day moving average of $24.04 and a 200-day moving average of $25.04.

Insider Activity

In other Patterson Companies news, CEO Donald Zurbay sold 7,216 shares of the firm’s stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $24.99, for a total value of $180,327.84. Following the completion of the sale, the chief executive officer now directly owns 230,072 shares of the company’s stock, valued at $5,749,499.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Les B. Korsh sold 2,842 shares of the business’s stock in a transaction that occurred on Wednesday, July 3rd. The shares were sold at an average price of $23.71, for a total value of $67,383.82. Following the sale, the insider now owns 103,765 shares of the company’s stock, valued at $2,460,268.15. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Donald Zurbay sold 7,216 shares of the firm’s stock in a transaction that occurred on Tuesday, July 16th. The stock was sold at an average price of $24.99, for a total transaction of $180,327.84. Following the completion of the transaction, the chief executive officer now directly owns 230,072 shares of the company’s stock, valued at $5,749,499.28. The disclosure for this sale can be found here. Insiders sold 17,149 shares of company stock valued at $415,851 in the last three months. Company insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Patterson Companies

A number of hedge funds and other institutional investors have recently bought and sold shares of PDCO. Illinois Municipal Retirement Fund purchased a new stake in shares of Patterson Companies in the first quarter worth about $1,339,000. Norges Bank purchased a new stake in Patterson Companies in the 4th quarter worth approximately $26,162,000. Sound Income Strategies LLC boosted its holdings in Patterson Companies by 10.3% in the 1st quarter. Sound Income Strategies LLC now owns 619,529 shares of the company’s stock valued at $17,130,000 after purchasing an additional 58,084 shares during the period. UniSuper Management Pty Ltd purchased a new position in shares of Patterson Companies during the 1st quarter valued at $535,000. Finally, Russell Investments Group Ltd. increased its holdings in shares of Patterson Companies by 1,802.5% in the first quarter. Russell Investments Group Ltd. now owns 67,615 shares of the company’s stock worth $1,870,000 after purchasing an additional 64,061 shares during the period. Institutional investors own 85.43% of the company’s stock.

Patterson Companies Company Profile

Patterson Companies, Inc engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada. The company operates through three segments: Dental, Animal Health, and Corporate segments. The Dental segment offers consumable products, including infection control, restorative materials, and instruments; basic and advanced technology and dental equipment; practice optimization solutions, such as practice management software, e-commerce, revenue cycle management, patient engagement solutions, and clinical and patient education systems.